SG11201806214RA - Clinical assessment of m-protein response in multiple myeloma - Google Patents
Clinical assessment of m-protein response in multiple myelomaInfo
- Publication number
- SG11201806214RA SG11201806214RA SG11201806214RA SG11201806214RA SG11201806214RA SG 11201806214R A SG11201806214R A SG 11201806214RA SG 11201806214R A SG11201806214R A SG 11201806214RA SG 11201806214R A SG11201806214R A SG 11201806214RA SG 11201806214R A SG11201806214R A SG 11201806214RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- clinical assessment
- mor202
- planegg
- Prior art date
Links
- 208000034578 Multiple myelomas Diseases 0.000 title abstract 2
- 206010035226 Plasma cell myeloma Diseases 0.000 title abstract 2
- 102000008100 Human Serum Albumin Human genes 0.000 abstract 1
- 108091006905 Human Serum Albumin Proteins 0.000 abstract 1
- 101710085938 Matrix protein Proteins 0.000 abstract 1
- 101710127721 Membrane protein Proteins 0.000 abstract 1
- 102100032965 Myomesin-2 Human genes 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
- G01N33/561—Immunoelectrophoresis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Ecology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Electrochemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16158714 | 2016-03-04 | ||
| PCT/EP2017/055011 WO2017149122A1 (fr) | 2016-03-04 | 2017-03-03 | Évaluation clinique de réponse de protéine m dans le myélome multiple |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806214RA true SG11201806214RA (en) | 2018-08-30 |
Family
ID=55745535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806214RA SG11201806214RA (en) | 2016-03-04 | 2017-03-03 | Clinical assessment of m-protein response in multiple myeloma |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11618789B2 (fr) |
| EP (1) | EP3423498A1 (fr) |
| JP (3) | JP7362250B2 (fr) |
| KR (1) | KR102427948B1 (fr) |
| CN (1) | CN108699161B (fr) |
| AU (2) | AU2017226960B2 (fr) |
| CA (1) | CA3016098A1 (fr) |
| IL (2) | IL260750B2 (fr) |
| SG (1) | SG11201806214RA (fr) |
| WO (1) | WO2017149122A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019209730A1 (fr) | 2018-04-24 | 2019-10-31 | Helena Laboratories Corporation | Élimination de facteurs d'interférence de profils d'électrophorèse de protéines sériques |
| CA3111651A1 (fr) | 2018-09-11 | 2020-03-19 | Jiangsu Hengrui Medicine Co., Ltd. | Anticorps anti-cd38, fragment de liaison a l'antigene de celui-ci, et utilisation pharmaceutique |
| AU2020242228A1 (en) | 2019-03-15 | 2021-07-22 | Morphosys Ag | Anti-CD38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
| WO2023094696A1 (fr) * | 2021-11-29 | 2023-06-01 | Morphosys Ag | Procédés de réduction d'interférence de médicament anti-cd38 mab dans des dosages sérologiques |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3912610A (en) * | 1974-07-23 | 1975-10-14 | Icl Scient | Method for electroquantitative determination of proteins |
| US4102990A (en) * | 1977-12-05 | 1978-07-25 | General Electric Company | Electrophoretic assay for antigen-antibody reaction based on particle-particle coupling |
| US4661586A (en) | 1981-11-17 | 1987-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Monoclonal anti-idiotype antibodies |
| US4578350A (en) * | 1983-09-23 | 1986-03-25 | Syntex (U.S.A.) Inc. | Immunoassays employing protected labels |
| US6936464B1 (en) * | 1992-10-02 | 2005-08-30 | Cancer Research Technology Limited | Immune responses to fusion proteins |
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| JP2003524587A (ja) | 1998-06-05 | 2003-08-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用 |
| EP1174440A1 (fr) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | Un épitope exprimé sélectivement sur la molécule humaine CD38 et détecté par un fragment d'un anticorps humain de forme scFv dérivé d'une librairie "phage display" |
| US7348139B1 (en) * | 2001-04-13 | 2008-03-25 | The Johns Hopkins University School Of Medicine | SOCS-1 gene methylation in cancer |
| US6902669B2 (en) | 2002-09-13 | 2005-06-07 | Fleetguard, Inc. | Filter cartridge with floating seal |
| EP1544215A1 (fr) | 2003-12-17 | 2005-06-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Fragments d'anticorps humains anti-idiotypiques imitant l'antigène Her-2/neu |
| CA2555185C (fr) * | 2004-02-06 | 2020-03-24 | Morphosys Ag | Anticorps humains anti-cd38 et utilisations de ceux-ci |
| SG142330A1 (en) | 2004-02-06 | 2008-05-28 | Morphosys Ag De | Anti-cd38 human antibodies and uses therefor |
| EP2548575A1 (fr) * | 2005-02-15 | 2013-01-23 | Duke University | Anticorps anti-CD19 avec activité ADCC pour le traitement des maladies autoimmunes |
| SI2567976T1 (sl) * | 2005-03-23 | 2017-11-30 | Genmab A/S | Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma |
| EP1888647A2 (fr) | 2005-05-24 | 2008-02-20 | MorphoSys AG | Production et profilage d'anticorps therapeutiques entierement humains hucal gold®; propres a la molecule cd38 humaine |
| SG10201400973XA (en) | 2005-10-12 | 2014-08-28 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| US8334365B2 (en) * | 2006-06-07 | 2012-12-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20080066739A1 (en) * | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
| US9382327B2 (en) * | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| EP1914242A1 (fr) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Nouveau anticorps Anti-CD38 pour le traitement du cancer |
| EP2193145A4 (fr) * | 2007-08-28 | 2011-05-18 | Abbott Biotech Ltd | Compositions et procédés comprenant des protéines de liaison pour adalimumab |
| WO2010002911A2 (fr) * | 2008-06-30 | 2010-01-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Procédés et matériaux pour la surveillance du myélome utilisant la spectrométrie de masse quantitative |
| WO2011154453A1 (fr) | 2010-06-09 | 2011-12-15 | Genmab A/S | Anticorps dirigés contre le cd38 humain |
| DK2621531T3 (en) * | 2010-09-27 | 2017-02-27 | Morphosys Ag | ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL |
| WO2012044612A1 (fr) | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Génération, caractérisation et utilisations d'anticorps anti-her3 |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| CA2869128C (fr) | 2012-03-30 | 2022-07-26 | The Board Of Regents Of The University Of Oklahoma | Polymeres d'heparosane de poids moleculaire eleve et procedes de production et d'utilisation de ceux-ci |
| EP2900232B1 (fr) * | 2012-09-25 | 2017-11-15 | MorphoSys AG | Combinaisons et leurs utilisations |
| PL3677591T3 (pl) | 2013-04-29 | 2023-06-26 | Teva Pharmaceuticals Australia Pty Ltd | Przeciwciała anty-cd38 i fuzje z interferonem alfa-2b o osłabionej aktywności |
| NZ719784A (en) | 2013-10-31 | 2022-02-25 | Sanofi Sa | Specific anti-cd38 antibodies for treating human cancers |
| BR112016017806B1 (pt) * | 2014-02-14 | 2023-05-02 | Cellectis | Uso de células t engenheiradas para imunoterapia contra células patológicas, e método ex vivo para preparação das mesmas |
-
2017
- 2017-03-03 IL IL260750A patent/IL260750B2/en unknown
- 2017-03-03 KR KR1020187026496A patent/KR102427948B1/ko active IP Right Grant
- 2017-03-03 CN CN201780014944.6A patent/CN108699161B/zh active Active
- 2017-03-03 AU AU2017226960A patent/AU2017226960B2/en active Active
- 2017-03-03 US US16/080,870 patent/US11618789B2/en active Active
- 2017-03-03 CA CA3016098A patent/CA3016098A1/fr active Pending
- 2017-03-03 WO PCT/EP2017/055011 patent/WO2017149122A1/fr active Application Filing
- 2017-03-03 IL IL305540A patent/IL305540B1/en unknown
- 2017-03-03 SG SG11201806214RA patent/SG11201806214RA/en unknown
- 2017-03-03 JP JP2018545438A patent/JP7362250B2/ja active Active
- 2017-03-03 EP EP17708766.5A patent/EP3423498A1/fr active Pending
-
2022
- 2022-02-03 JP JP2022015613A patent/JP7331168B2/ja active Active
-
2023
- 2023-02-14 US US18/168,930 patent/US20230203189A1/en active Pending
- 2023-08-08 JP JP2023129240A patent/JP2023157927A/ja active Pending
-
2024
- 2024-03-07 AU AU2024201503A patent/AU2024201503A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022058881A (ja) | 2022-04-12 |
| US20190077875A1 (en) | 2019-03-14 |
| AU2017226960B2 (en) | 2024-03-21 |
| IL260750B2 (en) | 2024-02-01 |
| AU2017226960A1 (en) | 2018-08-09 |
| US20230203189A1 (en) | 2023-06-29 |
| JP7362250B2 (ja) | 2023-10-17 |
| JP2019513346A (ja) | 2019-05-30 |
| WO2017149122A1 (fr) | 2017-09-08 |
| AU2024201503A1 (en) | 2024-03-28 |
| IL260750A (fr) | 2018-09-20 |
| KR102427948B1 (ko) | 2022-08-02 |
| CA3016098A1 (fr) | 2017-09-08 |
| US11618789B2 (en) | 2023-04-04 |
| JP7331168B2 (ja) | 2023-08-22 |
| CN108699161A (zh) | 2018-10-23 |
| IL305540A (en) | 2023-10-01 |
| JP2023157927A (ja) | 2023-10-26 |
| CN108699161B (zh) | 2022-06-03 |
| KR20180118151A (ko) | 2018-10-30 |
| IL305540B1 (en) | 2024-05-01 |
| EP3423498A1 (fr) | 2019-01-09 |
| IL260750B1 (en) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201910019PA (en) | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201807426WA (en) | Immunomodulators | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201806214RA (en) | Clinical assessment of m-protein response in multiple myeloma | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib |